| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MAPK13 |
| Uniprot No | O15264 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-365aa |
| 氨基酸序列 | MSLIRKKGFYKQDVNKTAWELPKTYVSPTHVGSGAYGSVCSAIDKRSGEKVAIKKLSRPFQSEIFAKRAYRELLLLKHMQHENVIGLLDVFTPASSLRNFYDFYLVMPFMQTDLQKIMGMEFSEEKIQYLVYQMLKGLKYIHSAGVVHRDLKPGNLAVNEDCELKILDFGLARHADAEMTGYVVTRWYRAPEVILSWMHYNQTVDIWSVGCIMAEMLTGKTLFKGKDYLDQLTQILKVTGVPGTEFVQKLNDKAAKSYIQSLPQTPRKDFTQLFPRASPQAADLLEKMLELDVDKRLTAAQALTHPFFEPFRDPEEETEAQQPFDDSLEHEKLTVDEWKQHIYKEIVNFSPIARKDSRRRSGMKL |
| 预测分子量 | 58.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MAPK13重组蛋白的模拟参考文献示例，供参考：
1. **文献名称**：*"High-yield expression and functional characterization of recombinant human MAPK13 in insect cells"*
**作者**：Chen L, et al.
**摘要**：本研究利用杆状病毒-昆虫细胞表达系统成功制备了高活性重组人MAPK13蛋白，并通过体外激酶实验证实其磷酸化底物ATF2的能力，为药物筛选提供了工具。
2. **文献名称**：*"Structural basis of MAPK13 activation by phosphorylation and its interaction with inhibitors"*
**作者**：Kim S, Park JH.
**摘要**：通过晶体结构解析，揭示了MAPK13在Thr180/Tyr182位点磷酸化后的构象变化，并阐明了小分子抑制剂选择性结合MAPK13的分子机制。
3. **文献名称**：*"Recombinant MAPK13 exacerbates oxidative stress in cardiac fibroblasts via NF-κB signaling"*
**作者**：Wang Y, et al.
**摘要**：实验表明，外源性重组MAPK13蛋白可激活心脏成纤维细胞中的NF-κB通路，加剧氧化应激反应，提示其在心脏纤维化中的潜在作用。
4. **文献名称**：*"Development of a MAPK13-specific monoclonal antibody using recombinant protein immunogen"*
**作者**：Garcia R, et al.
**摘要**：利用重组MAPK13蛋白作为免疫原，开发出高特异性单克隆抗体，并验证其在免疫印迹和免疫组化中的应用，助力MAPK13蛋白检测技术优化。
**备注**：以上文献为模拟示例，实际研究需通过PubMed、Google Scholar等平台以关键词“recombinant MAPK13”、“MAPK13 purification”或“MAPK13 kinase activity”检索最新文献。
**Background of MAPK13 Recombinant Protein**
Mitogen-activated protein kinase 13 (MAPK13), also known as p38δ, belongs to the p38 subfamily of MAP kinases, which are evolutionarily conserved serine/threonine kinases involved in regulating cellular responses to stress, inflammation, proliferation, and apoptosis. MAPK13 is activated by upstream kinases (e.g., MKK3/MKK6) through dual phosphorylation of its Thr-Gly-Tyr motif in the activation loop. It plays roles in diverse physiological and pathological processes, including cytokine production, cell differentiation, and tissue homeostasis, and has been implicated in diseases such as cancer, neurodegenerative disorders, and autoimmune conditions.
Recombinant MAPK13 protein is engineered using expression systems like *E. coli* or mammalian cells to ensure proper folding and post-translational modifications. The purified protein typically retains kinase activity, enabling studies on its enzymatic properties, substrate interactions, and regulatory mechanisms. Researchers utilize it to investigate MAPK13-specific signaling pathways, screen for inhibitors or activators, and validate drug targets. For example, its involvement in inflammation has made it a focus for developing therapeutics targeting chronic inflammatory diseases.
Structurally, recombinant MAPK13 often includes tags (e.g., His-tag) for affinity purification and detection. Quality assessments involve SDS-PAGE, Western blotting, and activity assays using substrates like ATF2 or HSP27. Its role in cancer progression, particularly in metastasis and drug resistance, has spurred interest in MAPK13 as a biomarker or therapeutic target.
Overall, MAPK13 recombinant protein serves as a critical tool for unraveling its biological functions and advancing translational research in precision medicine.
×
